Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-002 Capsules in Stage 3–4 CKD Patients with Secondary Hyperparathyroidism and Vitamin D Insufficiency
ChiCTR2600126426Phase 3Completed
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD) and Vitamin D deficiency (VDD) comparing NT-002 capsules with Placebo capsules (2 arms). Primary endpoints: plasma iPTH (intact parathyroid hormone) and hyperphosphatemia. Started Jun 2026; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on ChiCTR2600126426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126426.